Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 2;8(1):63.
doi: 10.3390/vaccines8010063.

A Review on Dengue Vaccine Development

Sheng-Qun Deng  1 , Xian Yang  1 , Yong Wei  1 , Jia-Ting Chen  1 , Xiao-Jun Wang  2 , Hong-Juan Peng  1
Affiliations
Review

A Review on Dengue Vaccine Development

Sheng-Qun Deng et al. Vaccines (Basel). .

Abstract

Dengue virus (DENV) has become a global health threat with about half of the world's population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus. Since there is no specific efficient medicine in treatment, it is urgent to develop vaccines to prevent infection and disease progression. Currently, only a live attenuated vaccine, chimeric yellow fever 17D-tetravalent dengue vaccine (CYD-TDV), has been licensed for clinical use in some countries, and many candidate vaccines are still under research and development. This review discusses the progress, strengths, and weaknesses of the five types of vaccines including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral vectored vaccine, and DNA vaccine.

Keywords: dengue fever; dengue virus; vaccine; vector-borne disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Clyde K., Kyle J.L., Harris E. Recent Advances in Deciphering Viral and Host Determinants of Dengue Virus Replication and Pathogenesis. J. Virol. 2006;80:11418–11431. doi: 10.1128/JVI.01257-06. - DOI - PMC - PubMed
    1. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition. World Health Organization; Geneva, Switzerland: 2009. [(accessed on 24 September 2019)]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK143157/ - PubMed
    1. Murrell S., Wu S.C., Butler M. Review of dengue virus and the development of a vaccine. Biotechnol. Adv. 2011;29:239–247. doi: 10.1016/j.biotechadv.2010.11.008. - DOI - PubMed
    1. Hammon W.M., Rundnick A., Sather G.E. Viruses Associated with Epidemic Hemorrhagic Fevers of the Philippines and Thailand. Science. 1960;131:1102–1103. doi: 10.1126/science.131.3407.1102. - DOI - PubMed
    1. Wu R.S.L., Chan K.R., Tan H.C., Chow A., Allen J.C., Ooi E.E. Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies. Antivir. Res. 2012;96:340–343. doi: 10.1016/j.antiviral.2012.09.018. - DOI - PubMed

LinkOut - more resources